| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $50.5M | -19.1% | +3.6% |
| SG&A Expense | $53.1M | +6.8% | +230.4% |
| Operating Income | -$103.5M | +7.6% | -59.8% |
| Net Income | -$102.2M | +7.1% | -58.5% |
| EPS (Basic) | -$0.90 | +8.2% | -36.4% |
| EPS (Diluted) | -$0.90 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $286.8M | +87.5% | +275.4% |
| Short-term Investments | $82.9M | -41.7% | +32.2% |
| Current Assets | $390.7M | +22.4% | +155.5% |
| Total Assets | $411.7M | +21.1% | +129.8% |
| Current Liabilities | $62.0M | +22.9% | +57.4% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$224.5M | — | — |
| Capital Expenditures | $570K | — | — |
| Investing Cash Flow | $179.7M | — | — |
| Financing Cash Flow | $155.1M | — | — |
| Free Cash Flow | -$225.1M | — | — |
| -36.4% |
| $99.6M |
| +100.2% |
| +98.8% |
| Total Liabilities | $166.7M | +56.2% | +66.8% |
| Stockholders' Equity | $245.0M | +5.0% | +209.4% |